Schmidt I Lopez, Lahner H, Mann K, Petersenn S
Division of Endocrinology, Medical Center, University of Essen, 45122 Essen, Germany.
J Clin Endocrinol Metab. 2003 Sep;88(9):4193-8. doi: 10.1210/jc.2002-021897.
The aim of the study was to evaluate the diagnostic value of the human CRH test and the basal morning serum cortisol for the diagnosis of adrenal insufficiency. Putative peak cortisol cut points for the CRH test and basal cortisol cut points were determined by receiver operating characteristic (ROC) analysis with the insulin tolerance test as reference test. Fifty-four patients with suspected hypothalamic-pituitary-adrenal disease were tested. In 20 healthy controls, CRH led to a mean peak cortisol of 594.8 +/- 21.7 nmol/liter. The lower limit of a normal response was calculated as 400 nmol/liter. ROC analysis of peak cortisol levels during CRH testing of patients with suspected hypothalamic-pituitary-adrenal disease suggested an optimal peak cortisol cut point of < or 377 nmol/liter for the diagnosis of adrenal insufficiency and a 96% specificity but poor sensitivity of 76%. The baseline cortisol in the healthy control group showed a mean of 439.3 +/- 24.9 nmol/liter, resulting in a lower limit of 267 nmol/liter. ROC analysis of patients suggested the highest accuracy for basal cortisol levels of 285 nmol/liter or more for the diagnosis of adrenal insufficiency (100% sensitivity and 61% specificity). Within this patient group, a cortisol of more than 98 nmol/liter excluded adrenal insufficiency among those without the disorder, yielding 100% specificity. Using these criteria of upper (285 nmol/liter) and lower (98 nmol/liter) cut-off points with high sensitivity and specificity can reduce the number of individuals who need provocative tests. Basal cortisol is less expensive, and we therefore suggest to use it as a first-line test of adrenal insufficiency. Because of the low sensitivity of the human CRH test, we do not recommend it as a second test.
本研究的目的是评估人促肾上腺皮质激素释放激素(CRH)试验及基础晨起血清皮质醇对肾上腺功能不全诊断的价值。以胰岛素耐量试验作为参考试验,通过受试者工作特征(ROC)分析确定CRH试验的假定皮质醇峰值切点及基础皮质醇切点。对54例疑似下丘脑 - 垂体 - 肾上腺疾病的患者进行了检测。在20名健康对照者中,CRH导致平均皮质醇峰值为594.8±21.7nmol/升。正常反应的下限计算为400nmol/升。对疑似下丘脑 - 垂体 - 肾上腺疾病患者进行CRH试验时皮质醇峰值水平的ROC分析表明,诊断肾上腺功能不全的最佳皮质醇峰值切点为≤377nmol/升,特异性为96%,但敏感性较差,为76%。健康对照组的基础皮质醇平均为439.3±24.9nmol/升,下限为267nmol/升。对患者的ROC分析表明,诊断肾上腺功能不全时基础皮质醇水平≥285nmol/升的准确性最高(敏感性100%,特异性61%)。在该患者组中,皮质醇>98nmol/升可排除无该疾病者的肾上腺功能不全,特异性为100%。使用这些具有高敏感性和特异性的上限(285nmol/升)和下限(98nmol/升)切点标准可减少需要激发试验的个体数量。基础皮质醇成本较低,因此我们建议将其作为肾上腺功能不全的一线检测方法。由于人CRH试验的敏感性较低,我们不建议将其作为第二项检测。